{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:37:37Z","timestamp":1792823857907,"version":"4.5.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disease characterized by heterotopic ossification in connective tissues. Few epidemiologic studies have investigated mortality rates among people with FOP. We conducted a retrospective cohort study to understand mortality in people with FOP. Data were obtained from people with FOP in the United States (US) who participated in either the International FOP Association (IFOPA) membership database or the IFOPA patient registry between January 1, 2017, and December 31, 2023. From 2017 to 2023, 250 people with FOP were identified. The age-adjusted mortality rate was 34.6 (95% CI: 22.5-51.7) deaths per 1000 person-years. The annual age-adjusted mortality rate ranged from 21.0 (95% CI: 3.2-77.8) to 51.6 (95% CI: 19.1-114.7) deaths per 1000 person-years; the annual age-adjusted mortality rate ranged from 7.2 to 8.9 per 1000 person-years in the general US population. The median age at death for people with FOP was 50.5 (95% CI: 46.5-57.5)\u00a0yr vs 80.5\u00a0yr in the general US population. The restricted mean time lost for people with FOP was 32.3 (95% CI: 26.8-37.8)\u00a0yr vs 8.1\u00a0yr in the general US population. The US FOP population has substantial excess mortality vs the general US population.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag154","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:49Z","timestamp":1789473889000},"source":"Crossref","is-referenced-by-count":0,"title":["Measures of mortality among people living with fibrodysplasia ossificans progressiva in the United States, 2017-2023"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-2510","authenticated-orcid":false,"given":"Alexander","family":"Breskin","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology, Regeneron Pharmaceuticals, Inc. , Tarrytown, NY 10591 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6729-1197","authenticated-orcid":false,"given":"Victor O","family":"Popoola","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology, Regeneron Pharmaceuticals, Inc. , Tarrytown, NY 10591 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6123-3391","authenticated-orcid":false,"given":"Michelle","family":"Davis","sequence":"additional","affiliation":[{"name":"International Fibrodysplasia Ossificans Progressiva Association , North Kansas City, MO 64116 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0435-7923","authenticated-orcid":false,"given":"Sammi","family":"Kile","sequence":"additional","affiliation":[{"name":"International Fibrodysplasia Ossificans Progressiva Association , North Kansas City, MO 64116 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9031-3544","authenticated-orcid":false,"given":"Amal","family":"Souttou","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology, Regeneron Pharmaceuticals, Inc. , Tarrytown, NY 10591 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3350-2245","authenticated-orcid":false,"given":"Susan","family":"Rhee","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology, Regeneron Pharmaceuticals, Inc. , Tarrytown, NY 10591 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-2111","authenticated-orcid":false,"given":"Caitlin","family":"Knox","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology, Regeneron Pharmaceuticals, Inc. , Tarrytown, NY 10591 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"1","key":"2026102401521196700_ref1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","article-title":"Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization","volume":"16","author":"Pignolo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2026102401521196700_ref2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/jbjs.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan","year":"2010","journal-title":"J Bone Joint Surg Am"},{"key":"2026102401521196700_ref3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1750-1172-6-80","article-title":"Fibrodysplasia ossificans progressiva: clinical and genetic aspects","volume":"6","author":"Pignolo","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"2026102401521196700_ref4","volume-title":"GeneReviews (Internet)","author":"Akesson","year":"2024"},{"issue":"Suppl 2","key":"2026102401521196700_ref5","first-page":"437","article-title":"Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons","volume":"10","author":"Pignolo","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"key":"2026102401521196700_ref6","volume-title":"FDA Approves First Treatment for Fibrodysplasia Ossificans Progressiva","author":"Food and Drug Administration"},{"key":"2026102401521196700_ops-bib-reference-mmuci4j2xhxtpksc","first-page":"2026","volume":"22","author":"Pasatru (garetosmab). Prescribing information. Regeneron Pharmaceuticals, Inc","year":"2026","journal-title":"Accessed September"},{"issue":"11","key":"2026102401521196700_ref7","doi-asserted-by":"publisher","first-page":"ziaf150","DOI":"10.1093\/jbmrpl\/ziaf150","article-title":"Medical guidelines for fibrodysplasia ossificans progressiva","volume":"9","author":"Kaplan","year":"2025","journal-title":"JBMR Plus"},{"issue":"1","key":"2026102401521196700_ref8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12891-020-3170-3","article-title":"Serum osteocalcin level is associated with the mortality in Chinese patients with fibrodysplasia ossificans progressiva aged \u226418\u2009years at diagnosis","volume":"21","author":"She","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"issue":"30","key":"2026102401521196700_ref9","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1002\/sim.5903","article-title":"Decomposition of number of life years lost according to causes of death","volume":"32","author":"Andersen","year":"2013","journal-title":"Stat Med"},{"issue":"12","key":"2026102401521196700_ref10","first-page":"1","article-title":"United States life tables, 2021","volume":"72","author":"Arias","year":"2023","journal-title":"Natl Vital Stat Rep"},{"key":"2026102401521196700_ref11","volume-title":"Underlying Cause of Death, 2018\u20132023, Single Race Request","author":"Centers for Disease Control and Prevention"},{"key":"2026102401521196700_ref12","doi-asserted-by":"crossref","volume-title":"Mortality in the United States, 2023","author":"Murphy","DOI":"10.15620\/cdc\/170564"},{"key":"2026102401521196700_ref13","first-page":"1","article-title":"Age adjustment using the 2000 projected U.S. population","volume":"20","author":"Klein","year":"2001","journal-title":"Healthy People 2000 Stat Notes"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag154\/71088644\/ziag154.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/11\/ziag154\/71088644\/ziag154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/11\/ziag154\/71088644\/ziag154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:52:23Z","timestamp":1792821143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag154\/8795981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag154","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,15]]},"article-number":"ziag154"}}